# Clinical Trial of Intranasal Delivery of NT-301

> **NCT06954428** · PHASE1 · COMPLETED · sponsor: **Nano PharmaSolutions Australia** · enrollment: 49 (actual)

## Conditions studied

- Tolerability of NT-301 Nasal Spray
- Pharmacokinetics of NT-301 Nasal Spray
- Safety of NT-301 Nasal Spray
- Performance of NT-301 Nasal Spray Device

## Interventions

- **COMBINATION_PRODUCT:** NT-301 1 mg
- **COMBINATION_PRODUCT:** NT-301 2 mg
- **COMBINATION_PRODUCT:** Placebo 1 mg
- **COMBINATION_PRODUCT:** Placebo 2 mg
- **COMBINATION_PRODUCT:** Placebo 3 mg
- **COMBINATION_PRODUCT:** NT-301 3 mg
- **COMBINATION_PRODUCT:** NT-301 4 mg
- **COMBINATION_PRODUCT:** Placebo 4 mg
- **DRUG:** Active Comparator: Movapo pen
- **DRUG:** Experimental: BA NT-301 strength 4 mg

## Key facts

- **NCT ID:** NCT06954428
- **Lead sponsor:** Nano PharmaSolutions Australia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-20
- **Primary completion:** 2025-12-12
- **Final completion:** 2025-12-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954428, "Clinical Trial of Intranasal Delivery of NT-301". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06954428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*